Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
0(0%)
Results Posted
200%(4 trials)
Terminated
3(60%)

Phase Distribution

Ph phase_3
2
40%
Ph phase_2
3
60%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(3)

Detailed Status

Terminated3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
40.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (60.0%)
Phase 32 (40.0%)

Trials by Status

completed240%
terminated360%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

NCT00626236
terminatedphase_2

Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

NCT03638466
terminatedphase_3

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)

NCT02691182
terminatedphase_3

Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment

NCT03597503
completedphase_2

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01364662

Clinical Trials (5)

Showing 5 of 5 trials
NCT00626236Phase 2

Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

Completed
NCT03638466Phase 2

Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

Terminated
NCT02691182Phase 3

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)

Terminated
NCT03597503Phase 3

Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment

Terminated
NCT01364662Phase 2

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5